<DOC>
	<DOCNO>NCT01930695</DOCNO>
	<brief_summary>The study design collect data performance confirm safety DX ( Diagnostic eXtension ) functionality Lumax 640/470 HF-T patient permanent atrial fibrillation CRT-D indication accord current ESC guideline . The DX functionality feature , activate Lumax 640/740 HF-T connect LinoxSMART S DX right ventricular lead . The combination device enable atrial sensing via sense dipole ventricular lead therefore reduces number implant lead without sacrifice atrial information . Atrial pace provide needed patient permanent atrial fibrillation .</brief_summary>
	<brief_title>Post Market Clinical Follow-up CRT-DX Therapy With Lumax 640/740 HF-T</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>CRTD indication accord current ESC guideline ( NYHA III/IV ; QRS≥120ms ; LVEF≤35 % ; Expected survival ≥ 1 year ; need pace slow ventricular rate pacemaker dependency result AV nodal ablation ventricular rate ≤60bpm rest ≤90bpm exercise ) Permanent atrial fibrillation Patients plan implanted BIOTRONIK Lumax 640/740 HFT Patients plan implanted BIOTRONIK LinoxSmart S DX right ventricular lead ( successor ) Patient eligible programming DX functionality accord physician ` decision Patient willing able comply CIP provide write informed consent Patient accept Home Monitoring® concept sufficient GSM/GPRS coverage Patients contraindication CRTD therapy Patients listed heart transplantation Life expectancy le 12 month Pregnant breastfeed woman Patients age 18 Patients limited contractual capability Participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>DX functionality</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>CRT-D indication</keyword>
</DOC>